title: Secondary solid tumors after allogeneic hematopoietic SCT in Japan.
abstract: To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age- and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS.
authors.affiliation: Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan. taroyok@xb4.so-net.ne.jp
authors.forename: A
authors.initials: A
authors.lastname: Yokota
authors.forename: S
authors.initials: S
authors.lastname: Ozawa
authors.forename: T
authors.initials: T
authors.lastname: Masanori
authors.forename: H
authors.initials: H
authors.lastname: Akiyama
authors.forename: K
authors.initials: K
authors.lastname: Ohshima
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: C
authors.initials: C
authors.lastname: Nakaseko
authors.forename: M
authors.initials: M
authors.lastname: Onoda
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: N
authors.initials: N
authors.lastname: Doki
authors.forename: N
authors.initials: N
authors.lastname: Aotsuka
authors.forename: H
authors.initials: H
authors.lastname: Kanamori
authors.forename: A
authors.initials: A
authors.lastname: Maruta
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008223:Lymphoma / Q000453:epidemiology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous